Circulating kidney injury molecule-1 (KIM-1) predicts survival outcomes in patients with metastatic renal cell carcinoma (mRCC), even in patients who have coexisting acute kidney injury (AKI) or ...

Correlates of immunotherapy response in metastatic clear cell renal cell carcinoma from circulating cell-free epigenomes. Association of baseline KIM-1 and KIM-1 change on treatment with outcomes.

Alan Tan, MD, discusses potential biomarkers that are being investigated to optimize treatment of patients with renal cell ...

Optimizing clear cell renal cell carcinoma tumor-infiltrating lymphocytes under controlled hypoxic conditions. Association of KIM-1 with PFS and OS in metastatic RCC. Multivariable models are adjusted ...

Plasma KIM-1 levels may be a useful, noninvasive biomarker for risk prognostication in metastatic RCC. Circulating kidney injury molecule-1 (KIM-1) predicts survival outcomes in patients with ...